Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus Ankara-human immunodeficiency virus vaccine vectors

Journal of Virology

Volumn 81, Issue 13, 2007, Pages 7022-7033

  Zhang, Xiugen ^a   Cassis Ghavami, Farah ^b   Eller, Mike ^c   Currier, Jeff ^c   Slike, Bonnie M ^c   Chen, Xuemin ^a   Tartaglia, James ^d   Marovich, Mary ^a   Spearman, Paul ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c US Military HIV Research Program   (United States)

^d Sanofi Pasteur   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANARYPOX VIRUS VECTOR; DRUG VEHICLE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MODIFIED VACCINIA VIRUS ANKARA VECTOR; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS DNA; VIRUS VECTOR;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CANARYPOX VIRUS; CONTROLLED STUDY; DENDRITIC CELL; DNA REPLICATION; ENVELOPE GENE; EXPRESSION VECTOR; GENE CASSETTE; GROUP SPECIFIC ANTIGEN GENE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; MAMMAL CELL; MODIFIED VACCINIA VIRUS ANKARA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PRO GENE; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

3T3 CELLS; AIDS VACCINES; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; APOPTOSIS; CANARYPOX VIRUS; CERCOPITHECUS AETHIOPS; CHICK EMBRYO; DENDRITIC CELLS; GENE EXPRESSION REGULATION, VIRAL; HELA CELLS; HIV-1; HUMANS; JURKAT CELLS; MICE; RETROVIRIDAE PROTEINS; SPECIES SPECIFICITY; T-LYMPHOCYTES; VACCINIA VIRUS; VERO CELLS;

CANARYPOX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MAMMALIA; POXVIRIDAE; VACCINIA VIRUS; VACCINIA VIRUS ANKARA;

EID: 34250869460     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02654-06     Document Type: Article

References (50)

1. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, M. A. Candida, N. L. Kozyr, P. L. Earl, J. M. Smith, H. L. Ma, B. D. Grimm, M. L. Hulsey, J. Miller, H. M. McClure, J. M. McNicholl, B. Moss, and H. L. Robinson. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69-74.
2. Amendola, A., G. Lombardi, S. Oliverio, V. Colizzi, and M. Piacentini. 1994. HIV-1 gp120-dependent induction of apoptosis in antigen-specific human T cell clones is characterized by 'tissue' transglutaminase expression and prevented by cyclosporin A. FEBS Lett. 339:258-264.
3. Bagetta, G., M. T. Corasaniti, W. Malorni, G. Rainaldi, L. Berliocchi, A. Finazzi-Agro, and G. Nistico. 1996. The HIV-1 gp120 causes ultrastructural changes typical of apoptosis in the rat cerebral cortex. Neuroreport 7:1722-1724.
4. Barouch, D. H., S. Santra, M. J. Kuroda, J. E. Schmitz, R. Plishka, A. Buckler-White, A. E. Gaitan, R. Zin, J. H. Nam, L. S. Wyatt, M. A. Lifton, C. E. Nickerson, B. Moss, D. C. Montefiori, V. M. Hirsch, and N. L. Letvin. 2001. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J. Virol. 75:5151-5158.
5. Belshe, R. B., G. J. Gorse, M. J. Mulligan, T. G. Evans, M. C. Keefer, J. L. Excler, A. M. Duliege, J. Tartaglia, W. I. Cox, J. McNamara, K. L. Hwang, A. Bradney, D. Montefiori, and K. J. Weinhold. 1998. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 12:2407-2415.
6. Belshe, R. B., C. Stevens, G. J. Gorse, S. Buchbinder, K. Weinhold, H. Sheppard, D. Stablein, S. Self, J. McNamara, S. Frey, J. Flores, J. L. Excler, M. Klein, R. E. Habib, A. M. Duliege, C. Harro, L. Corey, M. Keefer, M. Mulligan, P. Wright, C. Celum, F. Judson, K. Mayer, D. McKirnan, M. Marmor, and G. Woody. 2001. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J. Infect. Dis. 183:1343-1352.
7. Cao, H., P. Kaleebu, D. Hom, J. Flores, D. Agrawal, N. Jones, J. Serwanga, M. Okello, C. Walker, H. Sheppard, R. El-Habib, M. Klein, E. Mbidde, P. Mugyenyi, B. Walker, J. Ellner, and R. Mugerwa. 2003. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. J. Infect. Dis. 187:887-895.
8. Carroll, M. W., and B. Moss. 1995. E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses. BioTechniques 19:352-356.
9. Carroll, M. W., and B. Moss. 1997. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238: 198-211.
10. Cebere, I., L. Dorrell, H. McShane, A. Simmons, S. McCormack, C. Schmidt, C. Smith, M. Brooks, J. E. Roberts, S. C. Darwin, P. E. Fast, C. Conlon, S. Rowland-Jones, A. J. McMichael, and T. Hanke. 2006. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24:417-425.
11. Chahroudi, A., D. A. Garber, P. Reeves, L. Liu, D. Kalman, and M. B. Feinberg. 2006. Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus. J. Virol. 80:8469-8481.
12. Chen, X., M. T. Rock, J. Hammonds, J. Tartaglia, A. Shintani, J. Currier, B. Slike, J. E. Crowe, Jr., M. Marovich, and P. Spearman. 2005. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses. J. Virol. 79:5537-5547.
13. Cox, W. I., J. Tartaglia, and E. Paoletti. 1993. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 195:845-850.
14. Davies, M. V., H. W. Chang, B. L. Jacobs, and R. J. Kaufman. 1993. The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. J. Virol. 67:1688-1692.
15. de Bruyn, G., A. J. Rossini, Y. L. Chiu, D. Holman, M. L. Elizaga, S. E. Frey, D. Burke, T. G. Evans, L. Corey, and M. C. Keefer. 2004. Safety profile of recombinant canarypox HIV vaccines. Vaccine 22:704-713.
16. Egan, M. A., W. A. Pavlat, J. Tartaglia, E. Paoletti, K. J. Weinhold, M. L. Clements, and R. F. Siliciano. 1995. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1 MN env gene. J. Infect. Dis. 171:1623-1627.
17. Evans, T. G., M. C. Keefer, K. J. Weinhold, M. Wolff, D. Montefiori, G. J. Gorse, B. S. Graham, M. J. McElrath, M. L. Clements-Mann, M. J. Mulligan, P. Fast, M. C. Walker, J. L. Excler, A. M. Duliege, and J. Tartaglia. 1999. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J. Infect. Dis. 180:290-298.
18. Everett, H., and G. McFadden. 2002. Poxviruses and apoptosis: a time to die. Curr. Opin. Microbiol. 5:395-402.
19. Fang, Z. Y., I. Kuli-Zade, and P. Spearman. 1999. Efficient human immunodeficiency virus (HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate. J. Infect. Dis. 180:1122-1132.
20. Fang, Z. Y., K. Limbach, J. Tartaglia, J. Hammonds, X. Chen, and P. Spearman. 2001. Expression of vaccinia E3L and K3L genes by a novel recombinant canarypox HIV vaccine vector enhances HIV-1 pseudovirion production and inhibits apoptosis in human cells. Virology 291:272-284.
21. Fischer, S. F., H. Ludwig, J. Holzapfel, M. Kvansakul, L. Chen, D. C. Huang, G. Sutter, M. Knese, and G. Hacker. 2006. Modified vaccinia virus Ankara protein F1L is a novel BH3-domain-binding protein and acts together with the early viral protein E3L to block virus-associated apoptosis. Cell Death Differ. 13:109-118.
22. Franchini, G., S. Gurunathan, L. Baglyos, S. Plotkin, and J. Tartaglia. 2004. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev. Vaccines 3:S75-S88.
23. Goepfert, P. A., H. Horton, M. J. McElrath, S. Gurunathan, G. Ferrari, G. D. Tomaras, D. C. Montefiori, M. Allen, Y. L. Chiu, P. Spearman, J. D. Fuchs, B. A. Koblin, W. A. Blattner, S. Frey, M. C. Keefer, L. R. Baden, and L. Corey. 2005. High-dose recombinant canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J. Infect. Dis. 192:1249-1259.
24. Gupta, K., M. Hudgens, L. Corey, M. J. McElrath, K. Weinhold, D. C. Montefiori, G. J. Gorse, S. E. Frey, M. C. Keefer, T. G. Evans, R. Dolin, D. H. Schwartz, C. Harro, B. Graham, P. W. Spearman, M. Mulligan, and P. Goepfert. 2002. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group protocol 022A. J. Acquir. Immune Defic. Syndr. 29:254-261.
25. Hanke, T., R. V. Samuel, T. J. Blanchard, V. C. Neumann, T. M. Allen, J. E. Boyson, S. A. Sharpe, N. Cook, G. L. Smith, D. I. Watkins, M. P. Cranage, and A. J. McMichael. 1999. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73:7524-7532.
26. Hel, Z., J. Nacsa, W. P. Tsai, A. Thornton, L. Giuliani, J. Tartaglia, and G. Franchini. 2002. Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques. Virology 304:125-134.
27. Herbein, G., U. Mahlknecht, F. Batliwalla, P. Gregersen, T. Pappas, J. Butler, W. A. O'Brien, and E. Verdin. 1998. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 395:189-194.
28. Hornemann, S., O. Harlin, C. Staib, S. Kisling, V. Erfle, B. Kaspers, G. Hacker, and G. Sutter. 2003. Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L. J. Virol. 77:8394-8407.
29. Ignatius, R., M. Marovich, E. Mehlhop, L. Villamide, K. Mahnke, W. I. Cox, F. Isdell, S. S. Frankel, J. R. Mascola, R. M. Steinman, and M. Pope. 2000. Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion. J. Virol. 74:11329-11338.
30. Kapasi, A. A., G. Patel, N. Franki, and P. C. Singhal. 2002. HIV-1 gp120-induced tubular epithelial cell apoptosis is mediated through p38-MAPK phosphorylation. Mol. Med. 8:676-685.
31. Koopman, G., C. P. Reutelingsperger, G. A. Kuijten, R. M. Keehnen, S. T. Pals, and M. H. van Oers. 1994. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84: 1415-1420.
32. Lawson, V. A., K. A. Silburn, P. R. Gorry, G. Paukovic, D. F. Pureed, A. L. Greenway, and D. A. McPhee. 2004. Apoptosis induced in synchronized human immunodeficiency virus type 1-infected primary peripheral blood mononuclear cells is detected after the peak of CD4+ T-lymphocyte loss and is dependent on the tropism of the gp120 envelope glycoprotein. Virology 327:70-82.
33. Marovich, M. A., J. R. Mascola, M. A. Eller, M. K. Louder, P. A. Caudrelier, R. El-Habib, S. Ratto-Kim, J. H. Cox, J. R. Currier, B. L. Levine, C. H. June, W. B. Bernstein, M. L. Robb, B. Schuler-Thurner, R. M. Steinman, D. L. Birx, and S. Schlesinger-Frankel. 2002. Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells. J. Infect. Dis. 186:1242-1252.
34. Montefiori, D. C., J. T. Safrit, S. L. Lydy, A. P. Barry, M. Bilska, H. T. Vo, M. Klein, J. Tartaglia, H. L. Robinson, and B. Rovinski. 2001. Induction of neutralizing antibodies and Gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J. Virol. 75:5879-5890.
35. Moss, B. 1992. Poxvirus expression vectors. Curr. Top. Microbiol. Immunol. 158:25-38.
36. Moss, B. 1994. Replicating and host-restricted non-replicating vaccinia virus vectors for vaccine development. Dev. Biol. Stand. 82:55-63.
37. Najera, J. L., C. E. Gomez, E. Domingo-Gil, M. M. Gherardi, and M. Esteban. 2006. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J. Virol. 80:6033-6047.
38. Pincus, S., J. Tartaglia, and E. Paoletti. 1995. Poxvirus-based vectors as vaccine candidates. Biologicals 23:159-164.
39. Pitisuttithum, P. 2005. HIV-1 prophylactic vaccine trials in Thailand. Curr. HIV Res. 3:17-30.
40. Pogo, B. G., S. M. Melana, and J. Blaho. 2004. Poxvirus infection and apoptosis. Int. Rev. Immunol. 23:61-74.
41. Pugliese, O., M. Boirivant, and M. Viora. 1997. Apoptosis induction by human immunodeficiency virus type 1 (HIV-1) gp120 peptides. Viral Immunol. 10:95-102.
42. Ranasinghe, C., J. C. Medveczky, D. Woltring, K. Gao, S. Thomson, B. E. Coupar, D. B. Boyle, A. J. Ramsay, and I. A. Ramshaw. 2006. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1. Vaccine 24:5881-5895.
43. Reimann, J., and R. Schirmbeck. 1999. Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation. Immunol. Rev. 172:131-152.
44. Russell, N. D., B. S. Graham, M. C. Keefer, M. J. McElrath, S. G. Self, K. J. Weinhold, D. C. Montefiori, G. Ferrari, H. Horton, G. D. Tomaras, S. Gurunathan, L. Baglyos, S. E. Frey, M. J. Mulligan, C. D. Harro, S. P. Buchbinder, L. R. Baden, W. A. Blattner, B. A. Koblin, and L. Corey. 2007. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J. Acquir. Immune Defic. Syndr. 44:203-212.
45. Sancho, M. C., S. Schleich, G. Griffiths, and J. Krijnse-Locker. 2002. The block in assembly of modified vaccinia virus Ankara in HeLa cells reveals new insights into vaccinia virus morphogenesis. J. Virol. 76:8318-8334.
46. Singh-Sandhu, D., and J. Tartaglia. 2003. Poxviruses as immunization vehicles, p. 1297-1316. In S. A. Plotkin (ed.), Vaccines, 4th ed. Saunders, Philadelphia, PA.
47. Tartaglia, J., M. E. Perkus, J. Taylor, E. K. Norton, J. C. Audonnet, W. I. Cox, S. W. Davis, J. van der Hoeven, B. Meignier, M. Riviere, et al. 1992. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188:217-232.
48. Tartaglia, J., S. Pincus, and E. Paoletti. 1990. Poxvirus-based vectors as vaccine candidates. Crit. Rev. Immunol. 10:13-30.
49. Taylor, J., B. Meignier, J. Tartaglia, B. Languet, J. Van der Hoeven, G. Franchini, C. Trimarchi, and E. Paoletti. 1995. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 13:539-549.
50. Wyatt, L. S., B. Moss, and S. Rozenblatt. 1995. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology 210:202-205.